1. The content of the attached paper copy and the attached computer readable form of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;

2. The Sequence Listing does not add new matter; and

2. All statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further; that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 29, 2002

By: _____
William L. Strauss
Reg. No. 47,114

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Filing Date: March 14, 2001
Attorney Docket Number: 08647.0002-00000

APPENDIX TO AMENDMENT OF JULY 25, 2002

Version With Markings to Show Changes Made

Amendments to the Specification

Please replace the paragraph on page 17, beginning on line 12, with the following amended paragraph:

--Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the inventive compounds can be evaluated by known methods described in the literature (Harding, M.W. et al. *Nature* 341: 758-760 (1989); Holt et al. *J. Am. Chem. Soc.* 115: 9923-9938). These values are obtained as apparent K_i values and are presented in Table I. The *cis-trans* isomerization of an phenylalanine-proline bond in a model substrate, N-succinyl-Ala - Phe -Pro-Phe-*p*-nitroanilide (SEQ ID NO: 1), is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases *para*-nitroanilide from the *trans* form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent K_i values.--

Please replace the paragraph on page 17, beginning on line 23, with the following amended paragraph:

--In a plastic cuvette are added 950 µL of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 µL of FKBP (2.5 µM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 µL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 µL of test

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 µL of substrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide (SEQ ID NO: 1), 5 mg/mL in 2.35 mM LiCl in trifluoroethanol).--

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com